drugset

drugset / Trial / NCT06764628

A Study of SHR-4375 in Subjects With Solid Tumors

NCT06764628 ↗

Phase 1/2 Recruiting 208 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.

Timeline

Start: 2025-01-09
Primary completion: 2027-05
Completion: 2027-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-4375	Unknown	—	—

Indications